MacroGenics

company

About

MacroGenics is a biotechnology company developing immunotherapeutics to prevent autoimmune disorders, cancer and infectious diseases.

  • 501 - 1000

Details

Last Funding Type
Grant
Last Funding Money Raised
$9.80M
Industries
Biotechnology,Health Care,Manufacturing
Founded date
Jan 1, 2000
Number Of Employee
501 - 1000
Operating Status
Active

MacroGenics, Inc., a biotechnology company, focuses on the development, manufacture, and commercialization of immunotherapeutics for autoimmune disorders, cancer, and infectious diseases.

The company is developing immune-based products, including monoclonal antibodies; and vaccines to prevent infections in healthy individuals. The company's Fc engineering technology enables to improve antibody functions to eliminate cancer cells. It is also developing products around the Dual Activating ReTargeting technology.

The company was founded in 2000 and is headquartered in Rockville, Maryland.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
6
$135.40M
MacroGenics has raised a total of $135.40M in funding over 2 rounds. Their latest funding was raised on Jul 15, 2010 from a Grant round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jul 15, 2010 Grant $9.80M 1 National Institutes of Health Detail
Oct 23, 2008 Series D $25M 3 Detail
Jul 29, 2008 Series D $12.50M 1 Detail
May 17, 2006 Series C $45M 1 Detail
Oct 15, 2004 Series B $30.50M 3 TPG Detail

Investors

Number of Lead Investors
Number of Investors
2
6
MacroGenics is funded by 6 investors. National Institutes of Health and TPG are the most recent investors.
Investor Name Lead Investor Funding Round
National Institutes of Health Yes Grant
TPG Series D
CIDC Consultants Series D
Innovis Investments Series D
Cogene Ventures Series B
Hunt Ventures Series B